Plateaus on a GLP-1: what the trial curves show, and what a stall usually is

The word plateau gets used for two different things: a few weeks where the scale does not move, and the real flattening of the curve that every weight-loss method eventually reaches. The first is noise. The second is physiology. Telling them apart is most of the job.

What the published curves look like

Both pivotal trials plot mean body weight against time. The shape is the same in each: steep in the first months, slower through the middle, and flattening towards the end. In STEP 1, the semaglutide 2.4 mg curve reaches -14.9 percent at week 68 (PubMed 33567185). In SURMOUNT-1 the tirzepatide curves reach -15.0, -19.5 and -20.9 percent for 5, 10 and 15 mg at week 72, with the higher-dose curves still sloping gently downward at the final visit (PubMed 35658024).

Two measured points earlier in therapy help calibrate expectations. In STEP 4, participants had lost a mean 10.6 percent after 20 weeks of semaglutide escalation to 2.4 mg (PubMed 33755728). In SURMOUNT-4, participants had lost a mean 20.9 percent after 36 weeks of tirzepatide at 10 or 15 mg (PubMed 38078870). So the middle of therapy is where most of the loss happens, and the rate in month twelve is a fraction of the rate in month two. The week-by-week guide turns this into a table.

That slowing is the expected shape, not a problem. If your weekly rate at week 40 is a third of what it was at week 8, you are on the curve.

Why loss slows even when nothing changes

Energy expenditure falls as weight falls. A smaller body costs less to run and less to move, and there is an additional drop beyond what the weight change alone predicts. Hall and colleagues showed in 2011 that the old rule of 3,500 kcal per pound is wrong precisely because it ignores this: a fixed change in intake produces a curve that approaches a new plateau over years, with roughly half of the eventual change in the first year (PubMed 21872751). The GLP-1 reduces intake; the body's response to a lower weight is the same as with any other method.

Hormones move too. After a 10 percent loss by diet, Sumithran and colleagues found leptin, peptide YY, cholecystokinin, insulin and amylin lower and ghrelin higher, and the changes were still present a year later (PubMed 22029981). The medication blunts appetite, which is why people on it can hold a lower weight that would otherwise be hard to hold. It does not switch the underlying adaptation off.

Four flat weeks is not a plateau

A single weigh-in moves with water, salt, glycogen, bowel contents and the menstrual cycle. Four weekly readings inside half a percent of each other tell you very little, which is why the plateau checker refuses to give a verdict on fewer than four readings and uses a slope rather than two endpoints. See how to weigh yourself for a method that makes the numbers usable.

If the checker says you are flat while the trial curve at your week was still moving, work through this list before assuming anything about the medication:

• Doses. Any missed or late doses in the last six weeks? A late dose is not a plateau, it is a gap.
• Supply. Did the product, pharmacy or vial concentration change? Compounded products are not FDA approved and not interchangeable with brand products; a change in source is a change in what you are taking.
• Intake drift. Appetite suppression fades for some people between doses and over months. Liquid calories, alcohol, grazing and larger portions creep back without registering as hunger. Three honest days of notes usually show it.
• Training. Started or increased resistance training? Muscle gain masks fat loss on the scale. Measure your waist.
• Sleep and stress. Short sleep raises intake and shifts loss away from fat (see sleep).
• New medications. Some antidepressants, antipsychotics, steroids and glucose-lowering drugs move weight. Ask your pharmacist.
• Illness or injury. Inflammation and inactivity both hold water.

When to involve your prescriber

Bring it to the next appointment if the checker reads flat or gaining for eight weeks or more while you are taking every dose as prescribed, or sooner if the flat stretch comes with new symptoms. Take the checker output, your weekly weights and your notes. Do not change your dose or your schedule on your own; the trials that produced these curves used a fixed escalation, and dose decisions are the prescriber's. The FormBlends network's research digests hold the full trial numbers if you want them in hand.

The real plateau

At some point the curve flattens for good. In the trials that point was around a year to eighteen months on the label dose. A flat curve at that stage, with the medication continuing, is maintenance, and maintenance is the goal. The maintenance guide covers what the withdrawal trials say about the next decision.